var data={"title":"Pitavastatin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pitavastatin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/243701?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pitavastatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pitavastatin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8101006\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Livalo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8101007\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antilipemic Agent, HMG-CoA Reductase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119990\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary hyperlipidemia and mixed dyslipidemia:</b> Oral: Initial: 2 mg once daily; 4 weeks after initiation or upon titration, analyze lipid levels and adjust dose accordingly; Maintenance: 1 to 4 mg once daily; maximum: 4 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Individualize dose according to the baseline LDL-cholesterol levels, recommended goal of therapy, and patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prevention of cardiovascular disease/reduce the risk of ASCVD (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ACC/AHA Blood Cholesterol Guideline recommendations (ACC/AHA [Stone 2013]):</b> Adults &ge;21 years of age:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>LDL-C &ge;190 mg/dL:</i> High intensity therapy necessary; use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Type 1 or 2 diabetes and age 40 to 75 years:</i> Moderate intensity therapy: 2 to 4 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Type 1 or 2 diabetes, age 40 to 75 years, and an estimated 10-year ASCVD risk &ge;7.5%:</i> High intensity therapy necessary; use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Age 40 to 75 years and an estimated 10-year ASCVD risk &ge;7.5%:</i> Moderate to high intensity therapy: 2 to 4 mg once daily or consider using high intensity statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Secondary prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient has clinical ASCVD (eg, coronary heart disease, stroke/TIA, or peripheral arterial disease presumed to be of atherosclerotic origin) or is post-CABG (AHA [Kulik 2015]) <b>and:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Age &le;75 years:</i> High intensity therapy necessary; use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Age &gt;75 years or not a candidate for high intensity therapy:</i> Moderate intensity therapy: 2 to 4 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>NLA Dyslipidemia Guideline recommendations (NLA [Jacobson 2015]): </b>Adults &ge;20 years of age:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary or secondary prevention:</i>\n      <b> Note: </b>Treatment initiation using either moderate- or high-intensity statin therapy is recommended in qualifying patients based on ASCVD risk assessment criteria and baseline non-HDL-C and LDL-C values. Dosage should be individualized based on patient characteristics, tolerance to therapy, and with consideration for non-HDL-C and LDL-C treatment goals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate-intensity therapy (30% to 50% reduction of LDL-C generally): 2 to 4 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-intensity therapy (&ge;50% reduction of LDL-C generally): Use alternate statin therapy (eg, atorvastatin, rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with concomitant medications:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Erythromycin: Maximum pitavastatin dose: 1 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rifampin: Maximum pitavastatin dose: 2 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119991\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119992\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GFR &ge;60 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GFR 15 to 59 mL/minute/1.73 m<sup>2</sup> (not receiving hemodialysis): Initial: 1 mg once daily; maximum: 2 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD receiving hemodialysis: Initial: 1 mg once daily; maximum: 2 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119993\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22890514\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe muscle symptoms or fatigue:</b> Promptly discontinue use; evaluate CPK, creatinine, and urinalysis for myoglobinuria (Stone 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mild to moderate muscle symptoms:</b> Discontinue use until symptoms can be evaluated; evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases).  Upon resolution, resume the original or lower dose of pitavastatin. If muscle symptoms recur, discontinue pitavastatin use. After muscle symptom resolution, may then use a low dose of a different statin; gradually increase if tolerated. In the absence of continued statin use, if muscle symptoms or elevated CPK continues after 2 months, consider other causes of muscle symptoms. If determined to be due to another condition aside from statin use, may resume statin therapy at the original dose (Stone 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120023\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as calcium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Livalo: 1 mg, 2 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119911\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50429459\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Zypitamag (pitavastatin magnesium): FDA approved July 2017; anticipated availability is currently unknown. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119995\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with or without food; may take without regard to time of day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100960\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Primary hyperlipidemia and mixed dyslipidemia:</b> As an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adults with primary hyperlipidemia or mixed dyslipidemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470650\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cardiac risk reduction for noncardiac surgery (perioperative therapy); Noncardioembolic stroke/Transient ischemic attack (secondary prevention); Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8101005\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pitavastatin may be confused with atorvaSTATin, fluvastatin, lovastatin, nystatin, pravastatin, rosuvastatin, simvastatin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119922\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum glucose (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (4%), diarrhea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (&lt;2%), increased serum bilirubin (&lt;2%), increased serum transaminases (&lt;2%; usually transient)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (4%), myalgia (2% to 3%), arthralgia (&lt;2%), increased creatine phosphokinase (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distress, abdominal pain, cognitive dysfunction (reversible; including amnesia, confusion, forgetfulness, memory impairment), depression, dizziness, elevated glycosylated hemoglobin (Hb A1c), erectile dysfunction, fatigue, hepatic failure, hepatitis, hypoesthesia, immune-mediated necrotizing myopathy, insomnia, interstitial pulmonary disease, jaundice, malaise, muscle spasm, nausea, peripheral neuropathy, pruritus, myopathy, rhabdomyolysis (with acute renal failure), skin rash, urticaria, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119917\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pitavastatin or any component of the formulation; active liver disease, including unexplained persistent elevations of hepatic transaminase levels; pregnancy; lactation; coadministration with cyclosporine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119918\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Increases in HbA<sub>1c</sub> and fasting blood glucose have been reported; however, the benefits of statin therapy far outweigh the risk of dysglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Elevations in serum transaminases have been reported; elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy in most cases. Postmarketing reports of fatal and nonfatal hepatic failure have been reported and are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy promptly. If an alternate etiology is not identified, do not restart pitavastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated. Ethanol may enhance the potential of adverse hepatic effects; instruct patients to avoid excessive ethanol consumption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including rash, pruritus, and urticaria, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy/rhabdomyolysis: Rhabdomyolysis with acute renal failure secondary to myoglobinuria and/or myopathy has been reported; patients should be monitored closely. This risk is dose-related (doses &gt;4 mg) and is increased with concurrent use of erythromycin, protease inhibitors, fibric acid derivatives (eg, gemfibrozil), or niacin (doses &ge;1 g/day). If concurrent use is warranted, consider lower starting and maintenance doses of pitavastatin. Use caution in patients with inadequately treated hypothyroidism and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Immune-mediated necrotizing myopathy (IMNM) associated with HMG-CoA reductase inhibitors use has also been reported rarely. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing pitavastatin. Temporarily withhold therapy in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine, electrolyte disorders, and uncontrolled seizures). Discontinue therapy if markedly elevated CPK levels occur or myopathy is diagnosed/suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases; use with caution in patients who consume large amounts of ethanol or have a history of liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; these patients are predisposed to myopathy. Dosage adjustment required in patients with GFR &lt;60 mL/minute/1.73 m<sup>2</sup> including end-stage renal disease receiving hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special Populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients with advanced age; these patients are predisposed to myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). Based on current research and clinical guidelines, HMG-CoA reductase inhibitors should be continued in the perioperative period for noncardiac and cardiac surgery (ACC/AHA [Fleisher 2014]; ACC/AHA [Hillis 2011]). Perioperative discontinuation of statin therapy is associated with an increased risk of cardiac morbidity and mortality.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Has not been studied in Fredrickson types I, III, and V dyslipidemias. The effect on cardiovascular morbidity and mortality has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119945\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OATP1B1/SLCO1B1, UGT1A3, UGT2B7</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119946\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9532&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May increase the serum concentration of Pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Pitavastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of Pitavastatin. Management: Limit pitavastatin to a maximum of 1 mg/day (adult dose) when used in combination with erythromycin.  If this combination is used, monitor patients more closely for evidence of pitavastatin toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use whenever possible. Use is listed as contraindicated in product characteristic summaries in several countries, although UK labeling suggests that use could be considered under exceptional circumstances and with close supervision.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Pitavastatin. Gemfibrozil may increase the serum concentration of Pitavastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with glecaprevir/pibrentasvir and monitor for increased statin effects/toxicities. Avoid concomitant use with atorva-, simva-, or lovastatin. Limit rosuvastatin to 10 mg daily and reduce pravastatin dose 50%<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: HMG-CoA Reductase Inhibitors (Statins) may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of Pitavastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of Pitavastatin. Management: Canadian product labeling recommends use of the lowest pitavastatin dose with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: HMG-CoA Reductase Inhibitors (Statins) may enhance the hepatotoxic effect of PAZOPanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in the interaction. There is a lack of data regarding risk with other statins, but caution appears warranted with any statins. Atorvastatin should be avoided due to P-gp inhibition.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May increase the serum concentration of Pitavastatin. Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: May increase the serum concentration of Pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors (Statins) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: May increase the serum concentration of Pitavastatin.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119914\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">There are reports of congenital anomalies following maternal use of HMG-CoA reductase inhibitors in pregnancy; however, maternal disease, differences in specific agents used, and the low rates of exposure limit the interpretation of the available data (Godfrey 2012; Lecarpentier 2012). Cholesterol biosynthesis may be important in fetal development; serum cholesterol and triglycerides increase normally during pregnancy. The discontinuation of lipid lowering medications temporarily during pregnancy is not expected to have significant impact on the long term outcomes of primary hypercholesterolemia treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use of pitavastatin is contraindicated in pregnancy. Because they are potentially teratogenic, the ADA Diabetes guidelines recommends avoiding use of HMG-CoA reductase inhibitors in sexually active women of childbearing age who are not using reliable contraception (ADA 2018a). If treatment of dyslipidemias is needed in pregnant women or in women of reproductive age, other agents are preferred (Berglund 2012; Stone 2013). The manufacturer recommends administration to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16609546\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pitavastatin is present in breast milk. Due to the potential for serious adverse reactions in a breastfed infant, use while breastfeeding is contraindicated by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119994\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Red yeast rice contains variable amounts of several compounds that are structurally similar to HMG-CoA reductase inhibitors, primarily monacolin K (or mevinolin) which is structurally identical to lovastatin; concurrent use of red yeast rice with HMG-CoA reductase inhibitors may increase the incidence of adverse and toxic effects (Lapi 2008; Smith 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119997\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>2013 ACC/AHA Blood Cholesterol Guideline recommendations (Stone 2013):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lipid panel (total cholesterol, HDL, LDL, triglycerides):</b> Baseline lipid panel; fasting lipid profile within 4 to 12 weeks after initiation or dose adjustment and every 3 to 12 months (as clinically indicated) thereafter. If 2 consecutive LDL levels are &lt;40 mg/dL, consider decreasing the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatic transaminase levels:</b> Baseline measurement of hepatic transaminase levels (ie, ALT); measure hepatic function if symptoms suggest hepatotoxicity (eg, unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of skin or sclera) during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CPK:</b> CPK should not be routinely measured. Baseline CPK measurement is reasonable for some individuals (eg, family history of statin intolerance or muscle disease, clinical presentation, concomitant drug therapy that may increase risk of myopathy). May measure CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evaluate for new-onset diabetes mellitus during therapy; if diabetes develops, continue statin therapy and encourage adherence to a heart-healthy diet, physical activity, a healthy body weight, and tobacco cessation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If patient develops a confusional state or memory impairment, may evaluate patient for nonstatin causes (eg, exposure to other drugs), systemic and neuropsychiatric causes, and the possibility of adverse effects associated with statin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Manufacturer's labeling:</i> Liver enzyme tests at baseline and repeated when clinically indicated. Upon initiation or titration, lipid panel should be analyzed after 4 weeks of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49042860\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;\">\n      <b>Treatment goals: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]):</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Low risk (no risk factors):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;160 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ApoB: No recommendation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Moderate (&le;2 risk factors; 10-year risk &lt;10%) or high risk (diabetes; CKD stage 3 to 4; &ge;2 risk factors and 10-year risk 10% to 20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;90 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Very high risk (ACS; carotid/peripheral artery disease; diabetes or CKD stage 3 to 4 with &ge;1 risk factors; HeFH; 10-year risk &gt;20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Extreme risk (progressive atherosclerotic CVD after achieving LDL</i>\n      <i>&#8208;C &lt;70 mg/dL; CVD and diabetes, CKD stage 3 to 4, or HeFH; history of premature atherosclerotic CVD (&lt;55 years [males]; &lt;65 years [females]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;55 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>National Lipid Association Dyslipidemia recommendations (NLA [Jacobson 2015]):</b> Adults &ge;20 years:</p>\n    <p style=\"text-indent:0em;\">\n      <i>Low-, moderate-, or high-risk patient categories: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B &lt;90 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>For patients with diabetes plus 1 major ASCVD risk factor (ie, <i>high risk</i> category), treating to a non&ndash;HDL-C goal of &lt;100 mg/dL (LDL-C of &lt;70 mg/dL) may be considered.</p>\n    <p style=\"text-indent:0em;\">\n      <i>Very high-risk patient category:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B &lt;80 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119952\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA); this then results in a compensatory increase in the expression of LDL receptors on hepatocyte membranes and a stimulation of LDL catabolism. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects (de Denus 2002; Ray 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8119957\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~148 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99%, primarily to albumin and alpha 1-acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, via UGT1A3 and UGT2B7; minimal metabolism via CYP2C9 and CYP2C8</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 51%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (79%); urine (15%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322688\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Livalo Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (90): $994.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (90): $994.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (90): $994.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992814\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alipza (ES, PT);</li>\n      <li>Flovas (IN);</li>\n      <li>Guan Shuang (CN);</li>\n      <li>Lip Loss (BD);</li>\n      <li>Livalo (AU, BB, CN, JP, KR, TH, TW);</li>\n      <li>Livazo (AE, CH, DE, ES, GR, JO, LB, NL, PL, PT, SA, SE, UA);</li>\n      <li>Pavigard (BD);</li>\n      <li>Pitalip (TH);</li>\n      <li>Pitava (GR, VN);</li>\n      <li>Pitavas (BD);</li>\n      <li>Pivalo (BD);</li>\n      <li>Redevant (MX);</li>\n      <li>Trolise (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222384\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/22962670/pubmed\" target=\"_blank\" id=\"22962670\">22962670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cannon CP, Braunwald E, McCabe CH, et al, &ldquo;Intensive Versus Moderate Lipid Lowering With Statins After Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators,&rdquo; <i>N Engl J Med</i>, 2004, 350(15):1495-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/15007110/pubmed\" target=\"_blank\" id=\"15007110\">15007110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castro C and Gourley M, &quot;Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,&quot; <i>Ther Adv Musculoskelet Dis</i>, 2012, 4(2):111-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/22870499/pubmed\" target=\"_blank\" id=\"22870499\">22870499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(11):1749-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/12398573/pubmed\" target=\"_blank\" id=\"12398573\">12398573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo; <i>Chest</i>, 2008, 134(4):824-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/18689579/pubmed\" target=\"_blank\" id=\"18689579\">18689579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/25085961/pubmed\" target=\"_blank\" id=\"25085961\">25085961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godfrey LM, Erramouspe J, and Cleveland KW, &quot;Teratogenic Risk of Statins in Pregnancy,&quot; <i>Ann Pharmacother</i>, 2012, 46(10):1419-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/23032657/pubmed\" target=\"_blank\" id=\"23032657\">23032657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grundy SM, Cleeman JI, Merz CN, et al, &ldquo;Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,&rdquo; <i>J Am Coll Cardiol</i>, 2004, 44(3):720-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/15358046/pubmed\" target=\"_blank\" id=\"15358046\">15358046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo; <i>Circulation</i>, 2002, 105(12):1446-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/11914253/pubmed\" target=\"_blank\" id=\"11914253\">11914253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2012;126(7):e105]. <i>Circulation</i>. 2011;124(23):2610-2642. doi: 10.1161/CIR.0b013e31823b5fee.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169. doi: 10.1016/j.jacl.2015.02.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/25911072/pubmed\" target=\"_blank\" id=\"25911072\">25911072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/28437620/pubmed\" target=\"_blank\" id=\"28437620\">28437620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulik A, Ruel M, Jneid H, et al; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131 (10):927-964.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. <i>Br J Clin Pharmacol</i>. 2008;66(4):572-574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/18637891/pubmed\" target=\"_blank\" id=\"18637891\">18637891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo; <i>N Engl J Med</i>, 2005, 352(14):1425-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/15755765/pubmed\" target=\"_blank\" id=\"15755765\">15755765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lecarpentier E, Morel O, Fournier T, et al, &quot;Statins and Pregnancy: Between Supposed Risks and Theoretical Benefits,&quot; <i>Drugs</i>, 2012, 72(6):773-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/22480340/pubmed\" target=\"_blank\" id=\"22480340\">22480340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo; <i>Anesth Analg</i>, 2007, 104(6):1326-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/17513620/pubmed\" target=\"_blank\" id=\"17513620\">17513620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Livalo (pitavastatin) [prescribing information]. Montgomery, AL: Kowa Pharmaceuticals America; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo; <i>Lancet</i>, 2002, 360(9326):7-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/12114036/pubmed\" target=\"_blank\" id=\"12114036\">12114036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neuvonen PJ, Niemi M, and Backman JT, &ldquo;Drug Interactions with Lipid-lowering Drugs: Mechanisms and Clinical Relevance,&rdquo; <i>Clin Pharmacol Ther</i>, 2006, 80(6):565-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/17178259/pubmed\" target=\"_blank\" id=\"17178259\">17178259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo; Stroke, 2002, 33(9):2337-41. Available at http://stroke.ahajournals.org/cgi/content/short/33/9/233712215610</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo; <i>Circulation</i>, 2003, 107(14):1848-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/12695283/pubmed\" target=\"_blank\" id=\"12695283\">12695283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol</i>. 2005;46(8):1425-1433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/16226165/pubmed\" target=\"_blank\" id=\"16226165\">16226165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo; <i>N Engl J Med</i>, 2008, 359(21):2195-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/18997196/pubmed\" target=\"_blank\" id=\"18997196\">18997196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2003, 361(9364):1149-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/12686036/pubmed\" target=\"_blank\" id=\"12686036\">12686036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo; <i>N Engl J Med</i>, 1995, 333(20):1301-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/7566020/pubmed\" target=\"_blank\" id=\"7566020\">7566020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith DJ, Olive KE. Chinese red rice-induced myopathy. <i>South Med J</i>. 2003;96(12):1265-1267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/14696880/pubmed\" target=\"_blank\" id=\"14696880\">14696880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].<i>Circulation</i>. 2013; doi: 10.1161/01.cir.0000437738.63853.7a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tonelli M, Wanner C; for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline [published online ahead of print]. <i>Ann Intern Med</i>. 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pitavastatin-drug-information/abstract-text/24323134/pubmed\" target=\"_blank\" id=\"24323134\">24323134</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9532 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8101006\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8101007\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8119990\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8119991\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8119992\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8119993\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F22890514\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8120023\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8119911\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50429459\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8119995\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8100960\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470650\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8101005\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8119922\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8119917\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8119918\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8119945\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8119946\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8119914\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16609546\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8119994\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8119997\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F49042860\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8119952\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8119957\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322688\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992814\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9532|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pitavastatin-patient-drug-information\" class=\"drug drug_patient\">Pitavastatin: Patient drug information</a></li></ul></div></div>","javascript":null}